Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
March 15 2024 - 8:00AM
Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage
pharmaceutical company focused on developing next-generation oral
antibiotics to treat infections caused by multi-drug resistant
pathogens in community settings, announced today that the company
will participate in a virtual H.C. Wainwright @Home Fireside Chat
on March 21, 2024. Corey Fishman, Iterum’s Chief Executive Officer,
Sailaja Puttagunta, M.D., Iterum’s Chief Medical Officer, and Judy
Matthews, Iterum’s Chief Financial Officer, will discuss Iterum’s
lead program, oral sulopenem, for the treatment of adult women with
uncomplicated urinary tract infections (uUTI).
H.C. Wainwright @Home with Iterum Therapeutics plc
(ITRM)
Date: Thursday, March 21, 2024
Time: 10:00 A.M.- 11:00 A.M. Eastern Time
Format: Fireside Chat
Host: Ed Arce, Managing Director and Senior Healthcare
Analyst
Registration: Click here
The webcast presentation replay will be available for viewing on
the Events & Presentations section of Iterum’s website
following the presentation.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical
company dedicated to developing differentiated anti-infectives
aimed at combatting the global crisis of multi-drug resistant
pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world. Iterum is
currently advancing its first compound – sulopenem – a novel penem
anti-infective compound, in Phase 3 clinical development with an
oral formulation. Sulopenem also has an IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum has received Qualified Infectious Disease
Product (QIDP) and Fast Track designations for its oral and IV
formulations of sulopenem in seven indications. For more
information, please visit www.iterumtx.com.
Investor Contact:Judy Matthews Chief
Financial Officer312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024